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to estimate the prevalence of Sjögren’s syndrome (SS) in the adult Spanish population we performed 
a population-based multicenter cross-sectional study. Cases were defined by the American-European 
Consensus Group criteria proposed in 2002. A total of 4,916 subjects aged 20 years or over were 
included. the estimated prevalence of SS (including primary and secondary forms) in the adult 
population in Spain was 0.33% (95% CI 0.21–0.53). Extrapolating to the total population of the 
country aged ≥ 20 years (around 37.7 million persons), there would be around 125,000 cases of SS 
in Spain. Considering only primary SS, the estimated prevalence was 0.25% (95% CI 0.15–0.43) or 1 
person in 400. The prevalence of primary SS in Spain is comparable to that reported in other European 
studies with a similar design and diagnostic criteria. Based on these results, primary SS could not 
be considered a rare (orphan) disease. Only 50% of cases had already been diagnosed with SS prior 
EPISER 2016 study, confirming the existence of a non-negligible proportion of undiagnosed cases in 
the general population.
Sjögren’s syndrome (SS) is a chronic systemic autoimmune disease that mainly targets the exocrine glands, 
leading to dryness of the main mucosal surfaces and occasional glandular enlargement. In addition, a variety of 
systemic or extraglandular manifestations may occur, including fatigue, musculoskeletal symptoms, cutaneous 
lesions and internal organ involvement (e.g., pulmonary, renal, hepatic, and neurologic)1. Disease severity can 
vary over a wide  range1.
SS occurs in a primary form not associated with other diseases and a secondary form that complicates or 
overlaps with other rheumatic conditions, most commonly rheumatoid arthritis (RA), systemic lupus erythema-
tosus (SLE) and systemic sclerosis. Primary SS (pSS) is also associated with an increased risk of non-Hodgkin’s 
lymphoma (the lifetime risk of complications in SSp is approximately 5%)2.
Although the past few years have witnessed major advances involving B-cell hyperactivity in the pathogen-
esis of  pSS1, its etiology remains incompletely understood. The most frequently proposed hypothesis centers 
on the effects of multiple, mainly unknown, environmental factors affecting individuals with a specific genetic 
 susceptibility1.
Evaluations of the incidence and prevalence of pSS vary  widely3–24. Previous epidemiological studies have 
revealed discrepant prevalences, ranging from 0.01% to more than 3% of the general population, which has 
generated controversy about whether pSS should be considered a rare disease or  not3–26. It is unclear if these 
differences in prevalence reflect a real variability between populations or methodological differences (different 
diagnostic criteria and study designs).
It is critical to determine the prevalence of pSS to better understand its etiopathogenesis (assuming the 
existence of different rates between populations with different genetic and environmental backgrounds), and to 
determine the burden of the disease. In an era of increasing medical costs, financial constraints and managed 
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health care, we need reliable prevalence rates to help improve health care planning and disability compensation 
in countries with free and universal health coverage. Some studies have shown that health expenses of patients 
with pSS are double than those of the mean for primary care patients and similar to those of patients with  RA27,28.
The prevalence of SS has never been evaluated in Spain. This observation prompted the Spanish Society of 
Rheumatology (SER) to include this disease in EPISER 2016, a population-based study to estimate the prevalence 
of rheumatic diseases in the adult  population29. In addition to our study, we also performed a systematic review 
of epidemiologic studies of pSS that have evaluated its prevalence according to the 2002 revised American-
European Consensus Group (AECG)  criteria30 in order to compare their prevalence rates with our results. Using 
this approach, we hope to obtain a more reliable estimate of the variations in the prevalence of pSS.
Methods
Sample selection. The EPISER 2016 is an epidemiological study of the major rheumatic diseases (RA; 
SLE; symptomatic osteoartrhritis of the hand, knee, hip, cervical and lumbar spine; fibromyalgia; ankylosing 
spondylitis; psoriatic arthritis; Sjögren’s syndrome; gout; and symptomatic osteoporotic fracture) in the adult 
population in Spain undertaken by the Spanish Society of Rheumatology [Sociedad Española de Reumatología 
(SER)]. The rationale, methods, and general characteristics of the sample have been published  previously29,31.
Briefly, the EPISER 2016 is a multicenter, cross-sectional study that included 78 municipalities randomly 
selected throughout the 17 Spanish autonomous communities. A representative sample of adults aged 20 years 
or older and residing in the selected municipalities was selected by multistage stratified random sampling. We 
used the cutoff of 20 years of age because in the Spanish national statistics institute (INE), the census data are 
for 5-years periods, with the first of adulthood being 20–24 years.
Stratification was done by sex, age (in blocks of 10 years) and the rural/urban nature of the municipalities, 
in accordance with the distribution of the population in Spain. As EPISER 2016 included various diseases, for 
sample size calculation we focused on RA and psoriatic arthritis prevalence (a choice driven by convenience, 
based on the previous EPISER  200032. Assuming a Poisson distribution, a sample comprising 4,000 individuals 
would yield a 95% confidence interval (CI) of 0.30–0.77 for an expected prevalence of 0.5% (RA) and of 0.14–0.54 
for an expected prevalence of 0.3% (psoriatic arthritis). Based on an assumed missing values rate of 20%, we 
deemed it necessary to include around 5,000 individuals.
ethics. The study was first approved by the Research Ethics Committee of Hospital Universitario de Canarias 
(Acta 12/2016) and subsequently by the ethics committees of all the participant hospitals. All methods car-
ried out in accordance with relevant guidelines and regulations. Oral informed consent was obtained from all 
subjects during the initial telephone contact. Their agreement or regret was recorded. Additionally, written 
informed consent was obtained from all subjects who went to the participating centers for physical examination 
and complementary tests.
Recruitment of the selected population. From November 2016 to October 2017, the participants were 
contacted by using random digit dialing and a Computer Assisted Telephone Interviewing system (CATI) to 
conduct a questionnaire for the screening of the diseases under study. The survey was mostly performed via 
landlines, but in order to facilitate access to younger patients and expand the registry, we incorporated mobile 
phones beginning in March 2017, which represent 20.3% of the final sample. This figure reflects the proportion 
of homes in Spain that relied solely on a mobile telephone connection. Both for the randomized selection of 
telephones in each municipality as well as for conducting the initial screening interviews, an external company 
specialized in sociological studies was contracted, with experience in the areas of health and call center services 
(Ipsos España)31.
In cases of non-answered phone calls, a minimum of 6 attempts were made at different time frames. If after 
these attempts there was no answer or the subject refused to participate, another phone number within the same 
municipality was randomly selected.
The survey was divided into the following blocks of questions (see Annex 1 in Supplementary Material): 
sociodemographic, general health status, anthropometric and lifestyle (smoking and alcohol intake) variables, 
rheumatic disease screening and variables related to the use of health resources for osteoarticular problems 
(medical appointments and medications).
SS screening and confirmation of positive screening results. The screening comprised 2 comple-
mentary paths for all the participants. On the one hand, they were asked whether they had already been diag-
nosed with SS or Sicca syndrome. In addition, a screening was carried out based on symptoms related to ocular 
dryness and xerostomia (questions 45 to 52 in Annex 1).
If during the call center interview the participant mentioned having been diagnosed with SS or sicca syn-
drome, he or she was asked to identify the pertinent center and attending specialist. In those cases in which the 
individual was diagnosed at the referral hospital for the municipality, the consent of the patient was requested so 
that the rheumatologists who participated as researchers in that hospital could confirm the diagnosis by review-
ing the clinical history. If the individual was attended at a different center that was not the referral hospital in the 
municipality and the clinical record was not available, the patient’s permission was sought so that the researcher 
could contact his/her doctor.
Individuals who had not previously been diagnosed with SS, but who had a positive screening result based 
on symptoms, were contacted once again by phone to assess the clinical suspicion by means of a second, more 
specific questionnaire (see Annex 2 in Supplementary Material). This second telephone interview was carried 
out by the investigating rheumatologist from the referral hospital in the municipality.
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In those cases in which a suspicion of SS persisted after the second call, the subjects were offered an appoint-
ment with the investigating rheumatologist for diagnostic confirmation (physical examination and ancillary 
tests), according to the 2002 AECG  criteria30. These were applied to confirm those cases not diagnosed before the 
study. For previously diagnosed patients, no concerted effort was made to verify that they fulfilled these criteria 
based on their clinical history; clearly identifiable diagnoses were accepted regardless of the criteria applied.
Cases in which the subject completed the call center interview with a positive screening result for SS and the 
rheumatologist could not confirm or rule out the diagnosis were classified as missing.
Statistical analysis. The prevalence of SS and the 95% confidence interval (CI) were calculated consider-
ing the sample design. The weights were calculated depending on the selection probability for each stage of the 
sampling, taking as a reference the distribution of the population in Spain in 2016 according to Continuous 
Register Statistics from the Spanish Institute of Statistics. This weighing was carried out taking into account 
age (decades), sex, and geographic origin [3 zones were defined: North (Galicia + Asturias + Cantabria + Basque 
Country + Navarre + La Rioja), Mediterranean and the Canary Islands (Catalonia + Valencian Commu-
nity + Balearic Islands + Murcia + Andalusia + Canary Islands), and Center (Community of Madrid + Castile and 
León + Aragón + Castile-La Mancha + Extremadura)]; based on these characteristics each individual in the sam-
ple represented a certain number of individuals in the population (see Annex 4 in Supplementary Material).
Multivariate logistic regression was used to identify associations of sociodemographic, anthropometric and 
lifestyle variables with SS. Variable were included in the multivariate analysis when p < 0.2 in the bivariate analysis. 
Statistical significance was defined as p ≤ 0.05.
Finally, we also calculated the predictive positive value (PPV) for each of the questions of the screening 
questionnaire.
All analyses were performed using IBM SPSS Statistics v22.
Systematic review of the literature. In addition to our study, a systematic literature review according 
to the PRISMA  guidelines33 was conducted to identify all epidemiologic studies with data on the prevalence of 
pSS published up to December 2019.
Inclusion criteria for study selection (search filters) were as follows: (1) patients with primary pSS (those 
studies that included patients with secondary SS complicating other rheumatic conditions were excluded); (2) 
diagnosis of pSS according to the 2002 AECG  criteria30; (3) studies including only adults (> 18 years old); (4) 
study design: population-based studies and population surveys that examined an entire geographic region or 
that used a clearly defined random or clustered sampling procedure were included; reports consisting of surveys 
or audits in hospitals or clinics were excluded; (5) studies that reported the prevalence of pSS; and (6) studies in 
English, French, Spanish or Portuguese. No limitations were placed on ethnicity or human subjects.
Searches were conducted in PubMed for the period between January 1980 and December 2019 using the 
strategies recommended by the Cochrane Handbook. The PubMed comprehensive search strategy included 
the Mesh terms and keywords ("Sjögren’s Syndrome"[Mesh]) and ("Epidemiology"[Mesh] or epidemiol* or 
"Prevalence"[Mesh] or Prevalenc*). The reference lists of relevant articles were also reviewed to identify addi-
tional reports.
One reviewer (JN) collected the information from the included studies using ad hoc standard forms. Articles 
that did not fulfil all the inclusion criteria or that had insufficient data were excluded.
Results
prevalence of SS in Spain. A detailed flow chart of participants in the study is depicted in Fig. 1. A total of 
84,098 different phone numbers were dialed. Of these, 50,170 were wrong numbers or were unanswered; 28,784 
individuals refused to participate (96.9% of them refused at the very beginning of the interview), and 5,144 
complete interviews were completed. The response rate, once the individual had been contacted, was 15.2%.
The final sample comprised 4,916 individuals, mainly after removal of duplicate interviews or excess num-
bers in certain sample strata. Baseline characteristics of the whole sample and a comparison with the general 
population aged 20 years or older in Spain (reference population in EPISER2016) have been published in detail 
 elsewhere31. For the purposes of this study, the simple can be considered representative of the population aged 
20 years or over in  Spain31.
A total of 1,139 subjects (22.8%) had a positive screening for SS (call center questionnaire). A subsequent 
evaluation (review of their medical record and/or telephone call and medical consultation if needed) by a rheu-
matologist was possible in 1,069 subjects (none of the 70 missing subjects had reported a previous diagnosis of 
SS or Sicca syndrome).
Of these 1,069 subjects, 20 (1.87%) SS cases were detected, all of whom met the 2002 AECG  criteria30 (see 
Annex 5 in Supplementary Material). Only 50% (10/20) of these cases had already been diagnosed with SS prior 
to the EPISER study. Four cases were patients with secondary SS complicating RA (3) or SLE (1); the remaining 
16 were classified as pSS.
The estimated prevalence of SS (including primary and secondary forms) in the adult population in Spain was 
0.33% (95% CI 0.21–0.53). Extrapolating to the entire population of the country aged 20 years or older (around 
37.7 millions)34, there would be approximately 125,000 cases of SS in Spain.
Considering only pSS, the estimated prevalence of the disease was 0.25% (95% CI 0.15–0.43) or 1 person in 
400.
predictive value of pSS screening. The negative predictive value (NPV) among the 1,542 participants 
with a positive screening result for the other diseases included in EPISER 2016 (negative for SS) was 100% (0 
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cases of SS were detected). Additionally, in a pre-planned substudy on 209 subjects randomly selected among 
those with a negative screening result for all the diseases included in EPISER 2016, no SS cases were detected.
The positive predictive value (PPV) of the screening questionnaire was 1.87% (20 cases among the 1,069 
subjects with a positive screening result who completed the study).
Individual items of the screening questionnaire had a different PPV (see supplementary data 3). Reporting 
a previous diagnosis of SS or Sicca syndrome was the single best-discriminating item for SS (PPV 50%). Of the 
6 questions related to oral and ocular symptoms none had a discriminative value by itself, with a PPV of less 
than 7% in all case.
Among the 3 questions that evaluated the presence of ocular dryness, the use of artificial tears 3 or more 
times per day was the one that had a slightly higher PPV (6.4%). The PPV was similar for the 3 questions that 
investigated the presence of xerostomia.
Characteristics of the SS cases identified. The most important sociodemographic characteristics of 
the patients identified are shown in Table 1. Of the 20 patients, 17 were women (85%) and 3 (6%) were men, 
corresponding to a female-to-male ratio of 6:1. The mean age (standard deviation) of the subjects at the time of 
participation in the study was 57 (± 13.4) years. SS occurred more frequently between the fourth and fifth dec-
ades (50% of cases). Ninety five percent of the cases were subjects resident in urban municipalities.
Literature review. The PubMed search resulted in 1,934 non-overlapping article citations. A total of 1,899 
articles were excluded based on the screening of abstracts or titles, leaving 36 articles for the full-text review 
and assessment for eligibility. Twenty-nine of these articles were excluded after retrieving the full-text articles, 
Positive results for initial phone 
SS screening: 1139 
Phone numbers randomly 
dialed: 84,098 
Wrong or unanswered 
numbers: 50,170 
Individuals contacted: 33,928 
28,784 individuals 
refused to participatea
Complete interviews: 5144 
228 interviews excludedb
Study sample: 4916 
SS cases: 20 (16 with pSS)d 
70 individuals missingc
Figure 1.  Flowchart showing participants in the study. a27,892 refused in the very beginning of the phone 
call. bMainly after removal of duplicated interviews or excess numbers in certain sample strata. cNone of the 70 
missing subjects had reported a previous diagnosis of SS or Sicca syndrome. dOnly 50% (10/20) of these cases 
had already been diagnosed with SS prior to the EPISER2016 study.
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leaving 7 eligible studies for inclusion in the  review3,5,10,11,14–16 (Fig. 2). The main characteristics of these studies 
are summarized in Table 2. In all cases, the diagnosis of pSS was made according to the 2002 AECG  criteria30.
All studies were performed between 2004 and 2017; five reported prevalence rates in European 
 populations10,11,14–16 and two in the Americas (one in U.S. and one in South America)3,5. Various sources 
were used for case-finding purposes. In 5 studies, pSS cases were identified using questionnaires and clinical 
 examination5,10,11,15,16. Other sources included physician registries and medical record  databases3,14. One study 
only reported the prevalence of pSS in  women15.
Although all the studies used the same diagnostic criteria, discrepancies were observed in prevalence figures, 
ranging from 0.02% of the general population to 0.72% Population size significantly affected the evaluation of 
prevalence in patients with pSS. In general terms, the prevalence rate reported in small studies was higher than 
that in larger studies. In addition, there were important differences depending on the study design and the case-
finding methods employed, with population surveys based on sampling procedures and questionnaire-based 
surveys reporting higher prevalence rates than large population-based studies based on physician registries and 
medical record databases. These higher prevalences might stem in part from the fact that the tests required for 
disease classification according to the 2002 AECG criteria (ocular dryness objective assessments, salivary gland 
functional or morphologic tests, or salivary gland biopsies) are not always performed in clinical practice. This is 
reflected in the study by Maciel et al.3, based on manual medical records review, in which physician diagnoses 
yielded an age- and sex-adjusted pSS prevalence of 10.3 per 10,000 inhabitants, while according to AECG criteria, 
this prevalence was only 2.2 per 10,0003.
Taking into account these biases, in order to compare our results we focused only on those survey studies 
that evaluated the prevalence of pSS using a similar study design and case-finding method (sampling procedures 
and questionnaire based case-finding). Only five studies met these criteria (Table 2)5,10,11,15,16. Four were per-
formed in Europe, though one of these was not comparable to ours as it only investigated the prevalence of pSS 
in  women15. Of the remaining three, two were performed in  Greece10,16 and reported a prevalence of 0.23% and 
0.15%; the other one was conducted in Turkey and reported a prevalence of 0.21%11. The fifth was conducted in 
Brazil and reported a low prevalence compared to the European studies (0.06%), partly because it only included 
people aged 18–655.
Table 1.  Variables associated with the presence of Sjögren’s syndrome (SS). a This number is the remainder of 
taking 20 cases with confirmed SS and 70 missing subjects from the 4,916 individuals of the final sample. b One 
case in another European country and 1 case in South America.
Variable With SS (n = 20) Without SS (n = 4826a)
Bivariate analyses Multivariate analyses
p value Odds ratio (95% CI) p value
Age (years) 0.107
 20–39 2 (10%) 1,549 (32.1%)
 40–59 10 (50%) 1,856 (38.5%) 2,940 (0.627–13.776) 0.171
 ≥ 60 8 (40%) 1,421 (29.4%) 3.097 (0.642–14.948) 0.159
Gender (female) 17 (85%) 2,615 (54.2%) 0.006 3.967 (1.137–13.843) 0.031
Area of Spain 0.261
 North 9 (45%) 1,382 (28.6%)
 Center 4 (20%) 1,423 (29.5%)
 Mediterranean (+ Canary Islands) 7 (35%) 2,021 (41.9%)
Level of education 0.752
 Elementary 9 (45%) 1,796 (37.2%)
 Middle 5 (25%) 1,258 (26.1%)
 High 6 (30%) 1,767 (36.6%)
Body mass index 0.487
 Normal 12 (60%) 2,059 (44.4%)
 Underweight 0 54 (1.2%)
 Overweight 5 (25%) 1,847 (39.8%)
 Obese 3 (15%) 681 (14.7%))
Tobacco 0.900
 Never 10 (50%) 2,373 (49.2%)
 Before 6 (30%) 1,294 (26.8%)
 Active smoking 4 (20%) 1,159 (24%)
Birth abroad of Spain 2b (10%) 336 (7%) 0.646
Residence 0.062
 Rural 1 (5%) 1,098 (22.8%) 6.051 (0.809–42.285) 0.080
 Urban 19 (95%) 3,728 (77.2%)
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1934 non-overlapping citations identified through 
Pubmed search 
1899 citations excluded based on screening of 
abstracts or titles with general criteria 
36 potentially relevant articles 
identified for full-text review
7 Articles eligible for analysis 
29 articles excluded after ful-text review (review 
articles and comments, incidence data but not 
prevalence, duplicate data or population) 
Figure 2.  Flowchart showing article identification, inclusion and exclusion.
Table 2.  Summary of studies on the prevalence of primary Sjögren’s syndrome in the adult population 
(≥ 18 years old) using the 2002 American-European Consensus Group (AECG) criteria. a The study was only 
conducted in female population.
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Discussion
The prevalence of pSS had never been evaluated in Spain. Using a cross-sectional population study, we found that 
the prevalence of pSS in the general population of Spain was 0.25% (95% CI 0.15–0.43) or 1 person in 400. This 
prevalence is quite similar to those reported in other survey studies that have evaluated the prevalence of pSS 
in other European countries using a similar case-finding method and the same diagnostic criteria (0.15–0.23% 
in Greece and 0.21% in Turkey)10,11,16.
Based on these results, pSS should no longer be considered a “rare disease” in Spain. The European Com-
mission on Public Health defines a rare disease as a condition with prevalence below 1 in 2,000  persons35. With 
this cut-off point, in the majority of studies conducted in  Europe10,11,14–16 (regardless of the study design), pSS 
would similarly not be considered a “rare (orphan) disease” (Table 2). The question of whether pSS is rare or 
not has important consequences, not only for the public health system management of disease burden, but also 
for the development of future therapeutic agents for this indication. Indeed, the European Parliament and the 
Council adopted regulation (CE) No. 141/2000 on orphan drugs in 1999, which encourages the pharmaceutical 
and biotechnological industries to carry out research on and develop drugs to treat orphan  diseases26.
In the USA a disease is considered rare when it affects less than 200,000 people  nationwide36. Based on this 
cut-off point, in the two population-based study published to the date in U.S (the PR calculated in the study con-
ducted by Izmirly et al. was 13.1 per 100,000 person-years)3,24 pSS should not be considered a rare disease in this 
country. Supporting this impression, a recent meta-analysis of epidemiological studies in primary SS, computed 
an overall prevalence of 60.82 per 100,000 inhabitants worldwide or 1 person in 1,64425. There are 11 studies from 
Europe, which gave a pooled prevalence rate of 71.22 cases per 100,000 inhabitants (one case per 1,404 persons).
The fact that the estimated prevalence rates vary between studies with similar design and diagnostic/clas-
sification criteria (from 0.01 to 0.23% in Europe and 0.02 to 0.06% in America)4,9–11,14–17,24 supports the potential 
existence of geographical variations in disease prevalence due to different genetic backgrounds or environmental 
factors, without ruling out a possible confounding role of healthcare differences between countries. In this sense, 
Izmirly et al. recently revealed differences in the incidence rates among Manhattan residents based on race/
ethnicity in women, with Asian women ranking the  highest24.
In our country the prevalence of pSS is about three times lower than RA (0.9% in EPISER 2016)37, but quite 
similar to SLE (0.21%)38. In this sense, it has been speculated that pSS could be the most common systemic auto-
immune rheumatic disease (SARD) and the most underdiagnosed. Since usually it manifests with nonspecific 
symptoms like dry eyes, pain and fatigue, it is often overlooked and misdiagnosed for several  years39. Results from 
the EPISER 2016 confirm the existence of a non-negligible percentage of undiagnosed pSS cases in our commu-
nity (50% of the patients detected in our study had not been previously diagnosed). This fact could be important 
to explain why prevalence rates are lower in large population-based studies relying on physician registries and 
medical record databases, than in population surveys based on sampling procedures and questionnaire-based 
case-finding, even when performed in the same  country10, 15, 16. Supporting this impression, in our study only 
a small minority of patients with sicca symptoms have SS according to the 2002 AECG criteria (less than 2%).
As expected, pSS in Spain is much more frequent in women than in men. Most of cases are recorded between 
the fourth and fifth decades of life, although its occurrence in patients aged 60 years or older was common (40% 
of cases). Our findings are in line with a previous Spanish study which also observed 14% of cases in patients 
older than 70 years40. In this sense, the prevalence of pSS in the elderly European population seems to be between 
five to eight times higher than that of the general  population12,16,19. Several factors can contribute to this fact 
including a senile atrophy of the exocrine glands, higher rates of comorbidities such as diabetes and multidrug 
therapy, and the increased prevalence of autoantibodies documented in the  elderly41. Finally, interestingly the 
prevalence of SS seems to be higher in urban areas than in rural settings, a trend that needs to be confirmed. This 
fact has been previously reported by Broten et al. (J. Rheumatol 2014;41:673–679) in a study that analyzed the 
prevalence of systemic autoimmune rheumatic diseases (including SLE, systemic sclerosis, pSS and polymyositis/
dermatomyositis) across 7 Canadian provinces using population-based administrative data. After adjusting for 
demographics, they also observed a greater prevalence of SARDs in urban-versus-rural settings after adjusting 
for  demographics42. Living in urban or rural areas can have an impact on environmental factors. So, depending 
on where you life, you are exposed to different environmental factors, which is of importance since currently 
potential environmental triggers (such as viruses) are thought to participate in pSS pathogenesis. However, 
when interpreting the results of our study, one needs to consider that EPISER 2016 was primary designed to 
estimate the global prevalence of several rheumatic diseases in Spain. The analysis of the association with soci-
odemographic, anthropometric and lifestyle variables was a secondary objective and, for pathologies with a low 
prevalence such as pSS, the statistical power for this analysis is limited.
During the design of EPISER 2016 study other alternatives were considered, but phone calls were the best 
option in our context for access to the general population. In Spain there are no administrative claims that allow 
reliable estimates of prevalence for the entire country. There could be other alternatives to phone calls for recruit-
ment, such as postal mail, but the logistics were more complicated and a better response rate was not assured 
beforehand. In addition, the use of other different screening methods, such as identifying the cases directly 
from hospital/rheumatologists/electronic medical records, would not have allowed to detect undiagnosed cases.
Among the strengths of our study, it should be emphasized that criteria for SS symptomatic screening used in 
the first phone call allowed a very high sensitivity, similarly to what has been demonstrated in other rheumatic 
diseases also investigated in EPISER  201638,43,44. Moreover, the number of missing values among subjects with 
positive screening was low (70/1,139).
Although a response rate of 15.2% can be interpreted as a possible source of bias, previous revisions examin-
ing this question have concluded that a low response rate does not necessarily implies a non-response bias on 
their own when the reasons for non-participating are unrelated to the variables of interest in the  study45–48,49. 
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As we have already stated in previous publications of EPISER  201638,43,44, the response rate for calls in our study 
is similar to the most recent estimations for population-based telephone surveys and could be lower compared 
to other reports due to the demanding sampling requirements (strata based on rural/urban, sex and decades of 
age)50,51. These requirements, together with the similarity in the characteristics examined between the sample and 
the general population aged ≥ 20 years in Spain (reference population in EPISER 2016), as well as the weighting 
used in estimating the prevalence figures, indicate that the low response rate did not generate a significant bias 
invalidating the estimated  prevalence31,38,43,44.
conclusions
Even using the same classification criteria for pSS (the 2002 AECG criteria)30, the prevalence rates in the studies 
that analyzed this issue are very much influenced by population size, case source, and study design. This makes 
it a challenge to determine the true prevalence of the disease.
The EPISER 2016 study is the first to report the prevalence of pSS in Spain: 0.25% (95% CI 0.15–0.43) or 1 
person in 400. This prevalence is quite similar to that reported in other European studies with a similar design 
and diagnostic criteria (0.15–0.23% in Greece and 0.21% in Turkey)10,11,16. Thus, it could be inferred that the most 
reliable prevalence of pSS in the Mediterranean countries ranges between 0.20 and 0.25%.
Based on these results, SS cannot be considered a rare (orphan) disease. This study also confirms that a non-
negligible proportion of pSS cases in the general population remain undiagnosed. Strategies for outreach and 
management of such undiagnosed cases are still necessary. Reliable prevalence rates should help improve the 
planning of health-care and disability compensation in national systems with universal coverage.
Data availability
The authors confirm that all data underlying the findings are fully available without restriction. All relevant data 
are within the article.
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